Liquidia Corporation
LQDA
Pozycja w akcjach
#4846
Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating... Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension. Beyond its pipeline, the company also distributes a generic treprostinil injection within the U.S. market. Founded in 2004, Liquidia Corporation's main office is located in Morrisville, North Carolina.
Cena akcji
$34.12
Ostatnia synchronizacja: 2026-10-19
Kapitalizacja rynkowa
$3.05B
Zmiana (1 dzień)
-0.67%
Zmiana (1 rok)
39.61%
Kraj
US
Handel Liquidia Corporation (LQDA)
Kategoria
Healthcare
Wskaźnik P/S dla Liquidia Corporation (LQDA)
Wskaźnik P/S na dzień October 2026 TTM: 6.74
Według najnowszych raportów finansowych i ceny akcji Liquidia Corporation, obecny wskaźnik P/S (TTM) wynosi 6.74. Na koniec 2023 wynosił 44.71.
Historia wskaźnika P/S dla Liquidia Corporation od 2016 do 2026
Wskaźnik P/S na koniec każdego roku
| Rok | Wskaźnik P/S | Zmień |
|---|---|---|
| 2026 (TTM) | 6.74 | -89.81% |
| 2024 | 66.13 | 47.92% |
| 2023 | 44.71 | 83.47% |
| 2022 | 24.37 | 29.46% |
| 2021 | 18.82 | -86.07% |
| 2020 | 135.16 | 1,280.87% |
| 2019 | 9.79 | -82.92% |
| 2018 | 57.32 | 336.47% |
| 2017 | 13.13 | 82.10% |
| 2016 | 7.21 | 0.00% |
Wskaźnik P/S dla podobnych firm lub konkurentów
| Firma | Wskaźnik P/S | Różnica wskaźnika P/S | Kraj |
|---|---|---|---|
| 10.31 | 53.04% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| 2.36 | -64.97% |
HK
|
